Abstract
With several vitiligo therapies currently under development, a reliable clinician-reported outcome is needed to assess disease severity and treatment response. The objective of the current study is to evaluate inter- and intra-rater reliabilities of the F-VASI for assessing extent and severity of vitiligo in a central reader paradigm as part of a clinical trial of the oral, dual JAK3/TEC family kinase inhibitor ritlecitinib in patients with vitiligo. We found strong and consistent inter-rater agreement between two central readers across all F-VASI measurements and observed similar reliability for intra-rater assessments across 2 separate readings of the same patient images.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
